Pardeep Nijhawan Medicine Professional Corp is CEO & 10% at Edesa Biotech, Inc. (EDSA). They have made 5 open-market trades across 1 company since 2020, most recently 2022-06-30.
CIK 0001780021
5 open-market purchases totalling $65K since 2020, never a sale. Across 5 scored buys the stock is up 46.7% at ninety days, and 40.5 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| EDSA | 594,812 | $1.5M |
Shares reported on the most recent Form 4, priced at the 2022-07-05 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 80% | 60% |
| Avg Move | +4.3% | +19.7% | +46.7% |
| Alpha | +1.2% | +15.2% | +40.5% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EDSA | BUY | 2022-06-30 | 2022-07-05 | $1.60 | $32K | +0.0% | +17.7% | -32.9% |
| EDSA | BUY | 2022-03-31 | 2022-04-01 | $2.99 | $6K | -3.4% | -26.7% | -44.9% |
| EDSA | BUY | 2020-05-26 | 2020-05-28 | $2.98 | $9K | +0.3% | +51.7% | +86.8% |
| EDSA | BUY | 2020-03-29 | 2021-03-29 | $5.23 | $10K | +7.5% | +16.6% | +2.1% |
| EDSA | BUY | 2020-03-17 | 2020-03-19 | $1.87 | $7K | +16.9% | +39.3% | +222.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.